12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review

12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review

The article presents an analytical review of the use of aclidinium, formoterol, and combination of aclidinium and formoterol to treat chronic obstructive pulmonary disease (COPD) using a metered-dose dry powder inhaler Genuair® to administer a fixeddose combination. It is noted that twelve hours’ do...

Full description

Bibliographic Details
Main Authors:	A. A. Vizel, I. Yu. Vizel
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-10-01
Series:	Медицинский совет
Subjects:	copd double bronchodilation aclidinium formoterol genuair
Online Access:	https://www.med-sovet.pro/jour/article/view/2680

Similar Items

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
by: Miravitlles M, et al.
Published: (2016-08-01)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
by: Matera MG, et al.
Published: (2016-01-01)

A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study
by: Kostikas K, et al.
Published: (2022-09-01)

New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease
by: S N Avdeev, et al.
Published: (2019-03-01)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01)

Global initiative gold and national recommendations on the management of patients with chronic obstructive pulmonary disease (COPD): the place of double bronchodilation
by: A. A. Vizel, et al.
Published: (2019-12-01)

COPD Patients’ Behaviour When Involved in the Choice of Inhaler Device
by: Sorin Bivolaru, et al.
Published: (2023-05-01)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
by: Wise RA, et al.
Published: (2021-03-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
by: Li W, et al.
Published: (2023-11-01)

Comparison of Rapid Bronchodilatory Effects of Salmeterol and Formoterol in Patients with Moderate to Severe Asthma
by: Ebrahim Salehifar, et al.
Published: (2015-10-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)

Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)

Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study
by: Posthuma R, et al.
Published: (2023-06-01)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
by: Rebordosa C, et al.
Published: (2022-08-01)

Eficácia do formoterol na reversão imediata do broncoespasmo Efficacy of inhaled formoterol in reversing bronchoconstriction
by: Adalberto Sperb Rubin, et al.
Published: (2006-06-01)

Modern possibilities of correction of broncho-obstructive syndrome in chronic heart failure of ischemic origin in combination with chronic obstructive pulmonary disease: simple randomized parallel group study
by: Vladimir V. Evdokimov, et al.
Published: (2023-06-01)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
by: Wang C, et al.
Published: (2017-12-01)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01)

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
by: Ferguson GT, et al.
Published: (2016-10-01)

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis
by: Fabiano Di Marco, et al.
Published: (2018-01-01)

Do 'guidelines' really guide us?
by: Milićević-Nešić Ivana J.
Published: (2017-01-01)

Stable Clinical Course of Chronic Obstructive Pulmonary Disease Patients in the Era of Double Bronchodilator Therapy: A Single Referral Center Experience
by: Sun Hye Shin, et al.
Published: (2020-08-01)

The adjusted impact of different severities of acute exacerbations and medications on the risk of developing dementia in COPD patients
by: Kuo-Hua Chia, et al.
Published: (2023-03-01)

[Acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD)]
by: Domenico Lorenzo Urso
Published: (2017-07-01)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
by: Ichinose M, et al.
Published: (2016-08-01)

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
by: Singh S, et al.
Published: (2018-01-01)

When is dual bronchodilation indicated in COPD?
by: Thomas M, et al.
Published: (2017-08-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
by: Papi Alberto, et al.
Published: (2012-06-01)

PREVENTIVE EFFECT OF LONG ACTING Β2-AGONISTS ON STATIN INDUCED MYOPATHIES
by: Abdullah Qamar, et al.
Published: (2018-10-01)

Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation
by: Man KN, et al.
Published: (2018-06-01)

Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial
by: Machida K, et al.
Published: (2019-09-01)

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
by: Lopez-Campos JL, et al.
Published: (2017-06-01)

Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study
by: Diaz-Guzman Enrique, et al.
Published: (2011-10-01)

Pharmacological Treatment in Asthma and COPD
by: Tomoaki Hoshino, et al.
Published: (2009-01-01)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies
by: Ohar JA, et al.
Published: (2019-02-01)